Nirmatrelvir‐ritonavir therapy and COVID‐19 vaccination improve clinical outcomes of SARS‐CoV‐2 Omicron variant infection

• Published in: Journal of medical virology Vol. 95; no. 2; pp. e28497 - n/a
• Main Authors: Qi, Tangkai, Jin, Yinpeng, Wang, He, Liao, Yixin, Liu, Tiefu, Mao, Enqiang, Li, Feng, Li, Yinchuan, Fan, Xiaohong, Ling, Yun
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2023; John Wiley and Sons Inc
• Subjects: Adult; Aged; Antiretroviral drugs; Antiviral drugs; Clinical outcomes; Comorbidity; Coronaviruses; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; COVID‐19 vaccination; Disease Progression; Humans; Immunization; Infections; Length of stay; Matching; Nirmatrelvir‐ritonavir therapy; Older people; Omicron; Patients; rebound; Respiratory diseases; Retrospective Studies; Ritonavir; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Therapy; Vaccination; Viral diseases; Virology; rebound; Nirmatrelvir-ritonavir therapy; Omicron; disease progression; COVID-19 vaccination

To evaluate the effect of Nirmatrelvir‐ritonavir therapy and coronavirus disease 2019 (COVID‐19) vaccination on clinical outcomes of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron infection, we retrospectively analyzed the clinical data of 762 adult patients with confirmed Omic...